熊冬生课题组长期从事肿瘤靶向治疗新策略的研究，其中又以抗体及抗体偶联药物（ADC）的靶向治疗经验最为丰富，目前课题组拥有自主研发的多种针对肿瘤抗原、肿瘤干细胞抗原、肿瘤耐药蛋白（CD20、CD19、BCMA、CD123、P-GP等）的优秀单抗，率先开展了国内外高水平的抗体小型化先进研究，先后验证了Fab、F(ab’)2、Scfv、bispecfic diabody等抗体小片段在多种肿瘤尤其是耐药肿瘤治疗中的应用价值。在此基础上课题组成功对小型化抗体片段进行基因工程改造研究，联合力达霉素等先进抗癌药，研发出多种高效特异的新型ADC药物。近年，课题组创新性的开展“HUMSC体内运载抗体药物的二次靶向策略”的研究，新治疗体系将MSC细胞自身归巢特点与抗体靶向功能有机结合，最大限度的实现了针对肿瘤细胞的靶向治疗，在多种肿瘤中发挥了很好的抗癌作用。

1991 南开大学生物学生物化学硕士

1983 江西大学生物系微生物学学士

2004-2004  中国医学科学院血液病医院（中国医学科学院血液学研究所）研究员

1999-2004  中国医学科学院血液病医院（中国医学科学院血液学研究所）副研究员

1991-1999  中国医学科学院血液病医院（中国医学科学院血液学研究所）实习研究员，助理研究员

1983-1988  南昌味精厂助理工程师

1.国家自然科学基金“HUMSC介导的AFP特异启动子与microRNA122“多靶向”调控肝癌腺病毒治疗研究” (81572993)

2.国家“重大新药创制”科技重大专项“靶向CD20的抗肿瘤烯二炔强化抗体融合蛋白”(2012ZX09102301-015)

3.国家自然科学基金“基于抗体库和蛋白质谱分析发现新的白血病耐药相关膜蛋白” (30971291)

4.国家自然科学基金“基于化学生物学的耐药白血病治疗新靶点的发现” (30873091)

1. Yang Y, Zhang X, Lin F, Xiong M, Fan D, Yuan X, Lu Y, Song Y, Zhang Y, Hao M, Ye Z, Zhang Y, Wang J, Xiong D Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells J Hematol Oncol. 2019 Apr 25;12(1):46. doi: 10.1186/s13045-019-0723-8.

2. Zhang Q, Yuan XF, Lu Y, Li ZZ, Bao SQ, Zhang XL, Yang YY, Fan DM, Zhang YZ, Wu CX, Guo HX, Zhang YJ, Ye Z, Xiong DS Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells Int J Cancer. 2017 Oct 1;141(7):1445-1457. doi: 10.1002/ijc.30846. Epub 2017 Jul 7

3. Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z, Xiong D Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. J Hematol Oncol. 2017 Feb 23;10(1):56. doi: 10.1186/s13045-017-0397-z.

4. Yuan X, Zhang Q, Li Z, Zhang X, Bao S, Fan D, Ru Y, Dong S, Zhang Y, Ye Z, Xiong D Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically Cancer Lett. 2016 Jul 20;381(1):85-95.

5. Linlin Jiang, Ming Yang, Xiaoyun Zhang, Shiqi Bao,Li Ma, Dongmei Fan, Yuan Zhou, Dongsheng Xiong, and Yongsu Zhen A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity J Drug Target. 2016 Jan;24(1):47-57

6. Dongmei Fan, Wei Li, Yuqi Yang, Xiaolong Zhang, Qing Zhang, Yan Yan, Ming Yang,Jianxiang Wang1 and Dongsheng Xiong Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells J Hematol Oncol. 2015 Oct 6;8(1):108.

7. Zhang Y, Liu R, Fan D, Shi R, Yang M, Miao Q, Deng ZQ, Qian J, Zhen Y, Xiong D, Wang J The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3 Cancer Biol Ther. 2015 Oct;16(10):1514-25.

8. Yan C, Yang M, Li Z, Li S, Hu X, Fan D, Zhang Y, Wang J, Xiong D Umbilical Cord-derived Mesenchymal Stem Cells with sTRAIL Gene Expression Driven by AFP Promoter Suppress Orthotopically Implanted Hepatocarcinoma in Mice Biomaterials. 2014 Mar;35(9):3035-43

9. Ren S, She M, Li M, Zhou Q, Liu R, Lu H, Yang C, Xiong D The RNA/DNA-binding protein PSF relocates to cell membrane and contributes cells' sensitivity to antitumor drug, doxorubicin Cytometry A. 2014 Mar;85(3): 231-41

10. Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y, Zhang Y, Yagüe E, Xiong D Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo Breast Cancer Res Treat. 2014 Jan;143(2):287-99